Annals of Internal Medicine最新文献

筛选
英文 中文
Excessive Alcohol Use and Alcohol Use Disorders: A Policy Brief of the American College of Physicians. 过度饮酒和饮酒障碍:美国内科医师学会政策简报》。
Annals of Internal Medicine Pub Date : 2024-04-23 DOI: 10.7326/m23-3434
Ryan A. Crowley, David Hilden, Micah W. Beachy
{"title":"Excessive Alcohol Use and Alcohol Use Disorders: A Policy Brief of the American College of Physicians.","authors":"Ryan A. Crowley, David Hilden, Micah W. Beachy","doi":"10.7326/m23-3434","DOIUrl":"https://doi.org/10.7326/m23-3434","url":null,"abstract":"Alcohol is used by more people in the United States than tobacco, electronic nicotine delivery systems, or illicit drugs. Several health conditions, including cancer, cardiovascular disease, and liver disease, are associated with excessive alcohol use and alcohol use disorder. Nearly 30 million people aged 12 years or older in the United States reported past-year alcohol use disorder in 2022, but-despite its prevalence-alcohol use disorder is undertreated. In this policy brief, the American College of Physicians outlines the health effects of excessive alcohol use and alcohol use disorder, calls for policy changes to increase the availability of treatment of alcohol use disorder and excessive alcohol use, and recommends alcohol-related public health interventions.","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":"129 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140669290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Historical Redlining and Present-Day Nonsuicide Firearm Fatalities. 历史上的 "红线 "和今天的非自杀性枪支致死率。
Annals of Internal Medicine Pub Date : 2024-04-23 DOI: 10.7326/m23-2496
A. Dholakia, Kendall J. Burdick, C. Kreatsoulas, M. Monuteaux, Jennifer Tsai, S. V. Subramanian, E. Fleegler
{"title":"Historical Redlining and Present-Day Nonsuicide Firearm Fatalities.","authors":"A. Dholakia, Kendall J. Burdick, C. Kreatsoulas, M. Monuteaux, Jennifer Tsai, S. V. Subramanian, E. Fleegler","doi":"10.7326/m23-2496","DOIUrl":"https://doi.org/10.7326/m23-2496","url":null,"abstract":"BACKGROUND\u0000Redlining began in the 1930s with the Home Owners' Loan Corporation (HOLC); this discriminatory practice limited mortgage availability and reinforced concentrated poverty that still exists today. It is important to understand the potential health implications of this federally sanctioned segregation.\u0000\u0000\u0000OBJECTIVE\u0000To examine the relationship between historical redlining policies and present-day nonsuicide firearm fatalities.\u0000\u0000\u0000DESIGN\u0000Maps from the HOLC were overlaid with incidence of nonsuicide firearm fatalities from 2014 to 2022. A multilevel negative binomial regression model tested the association between modern-day firearm fatalities and HOLC historical grading (A [\"best\"] to D [\"hazardous\"]), controlling for year, HOLC area-level demographics, and state-level factors as fixed effects and a random intercept for city. Incidence rates (IRs) per 100 000 persons, incidence rate ratios (IRRs), and adjusted IRRs (aIRRs) for each HOLC grade were estimated using A-rated areas as the reference.\u0000\u0000\u0000SETTING\u0000202 cities with areas graded by the HOLC in the 1930s.\u0000\u0000\u0000PARTICIPANTS\u0000Population of the 8597 areas assessed by the HOLC.\u0000\u0000\u0000MEASUREMENTS\u0000Nonsuicide firearm fatalities.\u0000\u0000\u0000RESULTS\u0000From 2014 to 2022, a total of 41 428 nonsuicide firearm fatalities occurred in HOLC-graded areas. The firearm fatality rate increased as the HOLC grade progressed from A to D. In A-graded areas, the IR was 3.78 (95% CI, 3.52 to 4.05) per 100 000 persons per year. In B-graded areas, the IR, IRR, and aIRR relative to A areas were 7.43 (CI, 7.24 to 7.62) per 100 000 persons per year, 2.12 (CI, 1.94 to 2.32), and 1.42 (CI, 1.30 to 1.54), respectively. In C-graded areas, these values were 11.24 (CI, 11.08 to 11.40) per 100 000 persons per year, 3.78 (CI, 3.47 to 4.12), and 1.90 (CI, 1.75 to 2.07), respectively. In D-graded areas, these values were 16.26 (CI, 16.01 to 16.52) per 100 000 persons per year, 5.51 (CI, 5.05 to 6.02), and 2.07 (CI, 1.90 to 2.25), respectively.\u0000\u0000\u0000LIMITATION\u0000The Gun Violence Archive relies on media coverage and police reports.\u0000\u0000\u0000CONCLUSION\u0000Discriminatory redlining policies from 80 years ago are associated with nonsuicide firearm fatalities today.\u0000\u0000\u0000PRIMARY FUNDING SOURCE\u0000Fred Lovejoy Housestaff Research and Education Fund.","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":"9 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140666591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between the SaFETy Score and Self-reported Firearm Violence Among Young Adults Presenting to Emergency Departments in Three Cities: A Cross-Sectional Study. 三个城市急诊科就诊的年轻人中 SaFETy 分数与自我报告的持枪暴力之间的关系:一项横断面研究。
Annals of Internal Medicine Pub Date : 2024-04-23 DOI: 10.7326/m24-0026
Jason E. Goldstick, P. Carter, Lauren Whiteside, M. K. Delgado, Rebecca M. Cunningham
{"title":"Association Between the SaFETy Score and Self-reported Firearm Violence Among Young Adults Presenting to Emergency Departments in Three Cities: A Cross-Sectional Study.","authors":"Jason E. Goldstick, P. Carter, Lauren Whiteside, M. K. Delgado, Rebecca M. Cunningham","doi":"10.7326/m24-0026","DOIUrl":"https://doi.org/10.7326/m24-0026","url":null,"abstract":"","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":"8 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140666727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Annals Video Summary - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes. 年鉴》视频摘要 - 2 型糖尿病成人患者的新型药物治疗。
Annals of Internal Medicine Pub Date : 2024-04-19 DOI: 10.7326/M23-1554
{"title":"Annals Video Summary - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes.","authors":"","doi":"10.7326/M23-1554","DOIUrl":"https://doi.org/10.7326/M23-1554","url":null,"abstract":"","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":" January","pages":"eM231554"},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140682503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Untangling the Benefits of Time-Restricted Eating: Is It the Calories or the Time Restriction? 解读限时进食的益处:是卡路里还是时间限制?
Annals of Internal Medicine Pub Date : 2024-04-19 DOI: 10.7326/M24-0695
Krista A. Varady, Vanessa M. Oddo
{"title":"Untangling the Benefits of Time-Restricted Eating: Is It the Calories or the Time Restriction?","authors":"Krista A. Varady, Vanessa M. Oddo","doi":"10.7326/M24-0695","DOIUrl":"https://doi.org/10.7326/M24-0695","url":null,"abstract":"","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":" 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140684194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. 成人 2 型糖尿病患者的新型药物治疗:美国内科医师学会临床指南》。
Annals of Internal Medicine Pub Date : 2024-04-19 DOI: 10.7326/M23-2788
A. Qaseem, Adam J. Obley, Tatyana Shamliyan, Lauri A Hicks, Curtis S Harrod, Carolyn J. Crandall
{"title":"Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians.","authors":"A. Qaseem, Adam J. Obley, Tatyana Shamliyan, Lauri A Hicks, Curtis S Harrod, Carolyn J. Crandall","doi":"10.7326/M23-2788","DOIUrl":"https://doi.org/10.7326/M23-2788","url":null,"abstract":"DESCRIPTION\u0000The American College of Physicians (ACP) developed this clinical guideline to update recommendations on newer pharmacologic treatments of type 2 diabetes. This clinical guideline is based on the best available evidence for effectiveness, comparative benefits and harms, consideration of patients' values and preferences, and costs.\u0000\u0000\u0000METHODS\u0000This clinical guideline is based on a systematic review of the effectiveness and harms of newer pharmacologic treatments of type 2 diabetes, including glucagon-like peptide-1 (GLP-1) agonists, a GLP-1 agonist and glucose-dependent insulinotropic polypeptide agonist, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and long-acting insulins, used either as monotherapy or in combination with other medications. The Clinical Guidelines Committee prioritized the following outcomes, which were evaluated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach: all-cause mortality, major adverse cardiovascular events, myocardial infarction, stroke, hospitalization for congestive heart failure, progression of chronic kidney disease, serious adverse events, and severe hypoglycemia. Weight loss, as measured by percentage of participants who achieved at least 10% total body weight loss, was a prioritized outcome, but data were insufficient for network meta-analysis and were not rated with GRADE.\u0000\u0000\u0000AUDIENCE AND PATIENT POPULATION\u0000The audience for this clinical guideline is physicians and other clinicians. The population is nonpregnant adults with type 2 diabetes.\u0000\u0000\u0000RECOMMENDATION 1\u0000\u0000 ACP recommends adding a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or glucagon-like peptide-1 (GLP-1) agonist to metformin and lifestyle modifications in adults with type 2 diabetes and inadequate glycemic control (strong recommendation; high-certainty evidence).\u0000 \u0000\u0000 • Use an SGLT-2 inhibitor to reduce the risk for all-cause mortality, major adverse cardiovascular events, progression of chronic kidney disease, and hospitalization due to congestive heart failure.\u0000 \u0000\u0000 • Use a GLP-1 agonist to reduce the risk for all-cause mortality, major adverse cardiovascular events, and stroke.\u0000 \u0000\u0000\u0000RECOMMENDATION 2\u0000\u0000 ACP recommends against adding a dipeptidyl peptidase-4 (DPP-4) inhibitor to metformin and lifestyle modifications in adults with type 2 diabetes and inadequate glycemic control to reduce morbidity and all-cause mortality (strong recommendation; high-certainty evidence).","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":" 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140684434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians. 成人 2 型糖尿病患者的新型药物治疗:为美国内科医师学会撰写的《系统综述与网络 Meta 分析》。
Annals of Internal Medicine Pub Date : 2024-04-19 DOI: 10.7326/M23-1490
Tyler Drake, Adrienne Landsteiner, L. Langsetmo, R. MacDonald, Maylen Anthony, Caleb Kalinowski, Kristen E Ullman, Charles J Billington, Anjum S. Kaka, Shahnaz Sultan, Timothy J Wilt
{"title":"Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.","authors":"Tyler Drake, Adrienne Landsteiner, L. Langsetmo, R. MacDonald, Maylen Anthony, Caleb Kalinowski, Kristen E Ullman, Charles J Billington, Anjum S. Kaka, Shahnaz Sultan, Timothy J Wilt","doi":"10.7326/M23-1490","DOIUrl":"https://doi.org/10.7326/M23-1490","url":null,"abstract":"BACKGROUND\u0000Newer diabetes medications may have beneficial effects on mortality, cardiovascular outcomes, and renal outcomes.\u0000\u0000\u0000PURPOSE\u0000To evaluate the effectiveness, comparative effectiveness, and harms of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP1) agonists, dipeptidyl peptidase-4 (DPP4) inhibitors, and long-acting insulins as monotherapy or combination therapy in adults with type 2 diabetes mellitus (T2DM).\u0000\u0000\u0000DATA SOURCES\u0000MEDLINE and EMBASE for randomized controlled trials (RCTs) published from 2010 through January 2023.\u0000\u0000\u0000STUDY SELECTION\u0000RCTs lasting at least 52 weeks that included at least 500 adults with T2DM receiving eligible medications and reported any outcomes of interest.\u0000\u0000\u0000DATA EXTRACTION\u0000Data were abstracted by 1 reviewer and verified by a second. Independent, dual assessments of risk of bias and certainty of evidence (CoE) were done.\u0000\u0000\u0000DATA SYNTHESIS\u0000A total of 130 publications from 84 RCTs were identified. CoE was appraised using GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria for direct, indirect, and network meta-analysis (NMA); the highest CoE was reported. Compared with usual care, SGLT2 inhibitors and GLP1 agonists reduce all-cause mortality (high CoE) and major adverse cardiovascular events (MACE) (moderate to high CoE), SGLT2 inhibitors reduce progression of chronic kidney disease (CKD) and heart failure hospitalizations and GLP1 agonists reduce stroke (high CoE), and SGLT2 inhibitors reduce serious adverse events and severe hypoglycemia (high CoE). The threshold for minimally important differences, which was predefined with the American College of Physicians Clinical Guidelines Committee, was not met for these outcomes. Compared with usual care, insulin, tirzepatide, and DPP4 inhibitors do not reduce all-cause mortality (low to high CoE). Compared with insulin, SGLT2 inhibitors and GLP1 agonists reduce all-cause mortality (low to moderate CoE). Compared with DPP4 inhibitors, GLP1 agonists reduce all-cause mortality (moderate CoE). Compared with DPP4 inhibitors and sulfonylurea (SU), SGLT2 inhibitors reduce MACE (moderate to high CoE). Compared with SU and insulin, SGLT2 inhibitors and GLP1 agonists reduce severe hypoglycemia (low to high CoE).\u0000\u0000\u0000LIMITATIONS\u0000Infrequent direct comparisons between drugs of interest; sparse data for NMA on most outcomes; possible incoherence due to differences in baseline patient characteristics and usual care; insufficient data on predefined subgroups, including demographic subgroups, patients with prior cardiovascular disease, and treatment-naive persons.\u0000\u0000\u0000CONCLUSION\u0000In adults with T2DM, SGLT2 inhibitors and GLP1 agonists (but not DPP4 inhibitors, insulin, or tirzepatide) reduce all-cause mortality and MACE compared with usual care. SGLT2 inhibitors reduce CKD progression and heart failure hospitalization and GLP1 agonists reduce stroke compared with usual care. Serious adverse events and severe hypoglycemia are less fr","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":" 14","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140685137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Antibiotics for Resistant Infections: What Happens After Approval? 治疗耐药性感染的新抗生素:批准后会发生什么?
Annals of Internal Medicine Pub Date : 2024-04-19 DOI: 10.7326/M24-0192
J. Howard-Anderson, Helen W Boucher
{"title":"New Antibiotics for Resistant Infections: What Happens After Approval?","authors":"J. Howard-Anderson, Helen W Boucher","doi":"10.7326/M24-0192","DOIUrl":"https://doi.org/10.7326/M24-0192","url":null,"abstract":"","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":" 351","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140682381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacologic Treatments in Adults With Type 2 Diabetes: Cost-Effectiveness and Comorbidity Considerations. 成人 2 型糖尿病患者的药物治疗:成本效益和合并症考虑因素。
Annals of Internal Medicine Pub Date : 2024-04-19 DOI: 10.7326/M24-0861
Fatima Z. Syed
{"title":"Pharmacologic Treatments in Adults With Type 2 Diabetes: Cost-Effectiveness and Comorbidity Considerations.","authors":"Fatima Z. Syed","doi":"10.7326/M24-0861","DOIUrl":"https://doi.org/10.7326/M24-0861","url":null,"abstract":"","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":" 46","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140685636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Isocaloric, Time-Restricted Eating on Body Weight in Adults With Obesity : A Randomized Controlled Trial. 等热量、限时进食对成人肥胖症患者体重的影响:随机对照试验》(Effect of Isocaloric, Time-Restricted Eating on Body Weight in Adults With Obesity : A Randomized Controlled Trial)。
Annals of Internal Medicine Pub Date : 2024-04-19 DOI: 10.7326/M23-3132
N. Maruthur, Scott J. Pilla, Karen White, Beiwen Wu, May Thu Thu Maw, D. Duan, Ruth-Alma N. Turkson-Ocran, Di Zhao, J. Charleston, Courtney M Peterson, Ryan J Dougherty, J. Schrack, Lawrence J Appel, E. Guallar, J. Clark
{"title":"Effect of Isocaloric, Time-Restricted Eating on Body Weight in Adults With Obesity : A Randomized Controlled Trial.","authors":"N. Maruthur, Scott J. Pilla, Karen White, Beiwen Wu, May Thu Thu Maw, D. Duan, Ruth-Alma N. Turkson-Ocran, Di Zhao, J. Charleston, Courtney M Peterson, Ryan J Dougherty, J. Schrack, Lawrence J Appel, E. Guallar, J. Clark","doi":"10.7326/M23-3132","DOIUrl":"https://doi.org/10.7326/M23-3132","url":null,"abstract":"BACKGROUND\u0000Time-restricted eating (TRE) lowers body weight in many studies. Whether TRE induces weight loss independent of reductions in calorie intake, as seen in rodent studies, is unknown.\u0000\u0000\u0000OBJECTIVE\u0000To determine the effect of TRE versus a usual eating pattern (UEP) on body weight in the setting of stable caloric intake.\u0000\u0000\u0000DESIGN\u0000Randomized, isocaloric feeding study. (ClinicalTrials.gov: NCT03527368).\u0000\u0000\u0000SETTING\u0000Clinical research unit.\u0000\u0000\u0000PARTICIPANTS\u0000Adults with obesity and prediabetes or diet-controlled diabetes.\u0000\u0000\u0000INTERVENTION\u0000Participants were randomly assigned 1:1 to TRE (10-hour eating window, 80% of calories before 1 p.m.) or UEP (≤16-hour window, ≥50% of calories after 5 p.m.) for 12 weeks. Both groups had the same nutrient content and were isocaloric with total calories determined at baseline.\u0000\u0000\u0000MEASUREMENTS\u0000Primary outcome was change in body weight at 12 weeks. Secondary outcomes were fasting glucose, homeostatic model assessment for insulin resistance (HOMA-IR), glucose area under the curve by oral glucose tolerance test, and glycated albumin. We used linear mixed models to evaluate the effect of interventions on outcomes.\u0000\u0000\u0000RESULTS\u0000All 41 randomly assigned participants (mean age, 59 years; 93% women; 93% Black race; mean BMI, 36 kg/m2) completed the intervention. Baseline weight was 95.6 kg (95% CI, 89.6 to 101.6 kg) in the TRE group and 103.7 kg (CI, 95.3 to 112.0 kg) in the UEP group. At 12 weeks, weight decreased by 2.3 kg (CI, 1.0 to 3.5 kg) in the TRE group and by 2.6 kg (CI, 1.5 to 3.7 kg) in the UEP group (average difference TRE vs. UEP, 0.3 kg [CI, -1.2 to 1.9 kg]). Change in glycemic measures did not differ between groups.\u0000\u0000\u0000LIMITATION\u0000Small, single-site study; baseline differences in weight by group.\u0000\u0000\u0000CONCLUSION\u0000In the setting of isocaloric eating, TRE did not decrease weight or improve glucose homeostasis relative to a UEP, suggesting that any effects of TRE on weight in prior studies may be due to reductions in caloric intake.\u0000\u0000\u0000PRIMARY FUNDING SOURCE\u0000American Heart Association.","PeriodicalId":504151,"journal":{"name":"Annals of Internal Medicine","volume":" 45","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140685590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书